Sign inJoin waitlistJoin the waitlist

Marco Ruella

Scientific Director of the Lymphoma Program · University of Pennsylvania Health System

Credentials: · ·

History

University of Pennsylvania Health System
Present
University of Pennsylvania Health System · Perelman School of Medicine at the University of Pennsylvania
Present
University of Pennsylvania Health System
Present

University Surgical Associates
2018–2021
2016–2018
University of Pennsylvania
2012–2016
San Giovanni Basttista University Hospital and Umberto I Hospital
2008–2012
University of Turin
2007–2010
Federico II University
2007–2008
UNIV DI TORINO, TORINO
2003–2007

Research

Human chimeric antigen receptor macrophages for cancer immunotherapy
Nature Biotechnology · 2020 · 1,236 citations
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Cancer Discovery · 2015 · 1,091 citations
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Case report · Nature Medicine · 2018 · Co-first of 26 authors · 542 citations

Stephen Schuster
41 papers
Carl June
35 papers
Saar Gill
26 papers · 8 as a fellow
Jakub Svoboda
23 papers
David Porter
22 papers
Elise Chong
22 papers
Noelle Frey
17 papers
Sunita Nasta
17 papers
Alfred Garfall
16 papers
Daniel Landsburg
16 papers
SB
Stefan Barta
16 papers
Alberto Carturan
15 papers · 6 as a resident

Grants

The Role of IL-5 in CART Cell Immunotherapy for Cancer
National Cancer Institute · R01
PI · $685.1K · Mayo Clinic Rochester
2026–2031
Inhibition of ezh2 to Enhance Adoptive t-Cell Therapies for Cancer
National Cancer Institute · R01
Contact PI · $704K · University of Pennsylvania
2026–2031
CD5-Deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): A First-in-Human Phase I Clinical Trial
Food and Drug Administration · R01
PI · $3.4M · University of Pennsylvania
2025–2029
Selective B Cell Depletion Using Engineered T Cells As A Curative Treatment For Acquired Thrombotic Thrombocytopenic Purpura
National Heart, Lung, and Blood Institute · R01
PI · $1.6M · University of Pennsylvania
2025–2029